Ascendis Pharma A/S (BVMF:A1SN34)
Brazil
· Delayed Price · Currency is BRL 76.05
-2.52 (-3.21%)
At close: Mar 24, 2026
Ascendis Pharma Revenue
In the year 2025, Ascendis Pharma had annual revenue of 720.13M EUR with 98.03% growth. Ascendis Pharma had revenue of 247.50M in the quarter ending December 31, 2025, with 42.31% growth.
Revenue
720.13M EUR
Revenue Growth
+98.03%
P/S Ratio
14.74
Revenue / Employee
605.66K EUR
Employees
1,189
Market Cap
68.63B BRL
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 720.13M | 356.49M | 98.03% |
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rede D'Or São Luiz | 55.73B |
| Raia Drogasil | 44.25B |
| Hypera | 7.70B |
| Fleury | 8.29B |
| Odontoprev | 2.55B |
| Diagnósticos da América | 11.17B |
| Empreendimentos Pague Menos | 14.91B |
| Blau Farmacêutica | 1.70B |
Ascendis Pharma News
- 7 days ago - Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 - GlobeNewsWire
- 8 days ago - Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq - GlobeNewsWire
- 20 days ago - Ascendis Pharma to List Ordinary Shares Directly on Nasdaq - GlobeNewsWire
- 20 days ago - New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia - GlobeNewsWire
- 22 days ago - Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States - GlobeNewsWire
- 6 weeks ago - New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 - GlobeNewsWire
- 6 weeks ago - New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026 - GlobeNewsWire
- 2 months ago - Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire